Sobi to share new clinical data and research at EULAR 2025
STOCKHOLM, May 28, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) will present new clinical data and research outcomes at the annual European Congress of Rheumatology (EULAR 2025) in Barcelona from the 11-14 June 2025. Research will include clinical trial outcomes on the efficacy and safety of Gamifant in the treatment of macrophage activating syndrome, updates on trial details of Vonjo investigating the potential treatment of VEXAS, and an analysis on the management of uncontrolled gout.
Sobi will host a symposium on the dermatologic, rheumatologic, and hematologic features of VEXAS syndrome during the congress. The symposium will be chaired by Dr Sophie Georgin-Lavialle MD, PhD from the French National Reference Centre for auto-inflammatory diseases and inflammatory amyloidosis. The symposium will be followed by a panel discussion and Q&A.
"We are delighted that our continued advancements in treating rare disease, including those suffering with the most debilitating rheumatology conditions will be presented at this year's EULAR conference. Sobi's presentations will provide insights and treatment options for those working with patients with rheumatological conditions, providing them with the most up-to-date clinical data and approaches," said Lydia Abad-Franch, MD, MBA, Head of Research, Development, and Medical Affairs (RDMA), and Chief Medical Officer at Sobi.
"With several poster and oral presentations and a longer form symposium, we are proud to be able to show how research and collaboration can advance clinical practice – and we look forward to meeting and connecting with colleagues in Barcelona," Lydia Abad-Franch concluded.
Key data to be presented at EULAR 2025
Gamifant (emapalumab)
Efficacy and Safety of emapalumab in Patients with Macrophage Activation Syndrome in Still's disease: Results from a Pooled Analysis of Two Prospective Trials
Speaker: Professor Fabrizio De Benedetti (principal investigator of the study)
Oral presentation
Session title: Clinical Abstract Session: Proceedings in Juvenile Idiopathic Arthritis
Session date: Thursday 12 June
Session time: 10:30 - 12:00 CEST
Presentation time: 10:48 - 10:57 CEST
Location: Room 6.1
Exposure-safety analysis from two clinical trials of emapalumab in patients with macrophage activation syndrome in Still's disease
Speaker: Professor Fabrizio De Benedetti (principal investigator of the study)
Poster presentation
Session title: Poster View VI
Session date: Friday 13 June
Session time: 12:00 – 13:30 CEST
Location: Poster Hall
NASP (formerly SEL-212)
Variations in uncontrolled gout between Rheumatologists and Nephrologists
Poster presentation
Session title: Poster View VIII
Session date: Friday 13 June
Session time: 10:15 - 11:45 CEST
Location: Poster Hall
Vonjo (pacritinib)
Development of a Consensus Definition of VEXAS Flare for Use in Clinical Research
Poster presentation
Session title: Poster View VII
Session date: Friday 13 June
Session time: 14 :45 - 15 :45 CEST
Location: Poster Hall
PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome
Poster tour
Session Title: Poster Tour II/ Clinical and Basic Poster Tours: Autoinflammatory Diseases including VEXAS
Session date: Saturday 14 June
Session time: 10:15 -11:45 CEST
Presentation time: 10:29 - 10:36 CEST (4 mins + 2 mins Q&A)
Location: Poster Tour II
Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS-DAI)
Poster tour
Session title: Poster Tour II/ Clinical and Basic Poster Tours: Autoinflammatory Diseases including VEXAS
Session date: Saturday 14 June
Session time: 10:15 - 11:45 CEST
Presentation time: 10:43 - 10:50 CEST (4 mins + 2 mins Q&A)
Location: Poster Tour II
Medical Symposium
An in-depth presentation on VEXAS syndrome: the dermatologic, rheumatologic, and hematologic features of the condition. Followed by a panel discussion and Q&A
Symposium title: Putting on your VEXAS goggles: Seeing what's in plain sight
Session date: Friday 13 June
Session time: 17:30 - 18:30 CEST
Location: Fira de Barcelona, Room B4
About Gamifant® (emapalumab)
Gamifant® (emapalumab) is indicated for the treatment of adult and paediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy.
About Macrophage activation syndrome (MAS)
Macrophage activation syndrome (MAS) is a potentially life-threatening complication of Still's disease characterised by interferon-gamma (IFNγ)–driven systemic hyperinflammation. More than one-third of patients inadequately respond to high-dose glucocorticoids. Emapalumab, an anti-IFNγ antibody, demonstrated efficacy and safety in a phase 2 pilot study in patients with MAS in Still's disease and an inadequate response to high-dose glucocorticoids.
About NASP, formerly SEL-212
NASP is a novel investigational medicine designed to reduce serum urate (SU) levels in people with uncontrolled gout, potentially reducing harmful tissue urate deposits which when left untreated can lead to debilitating gout flares and joint deformity. NASP is administered every 4-weeks as a sequential, two-component, infusion therapy consisting of tolerogenic nanoencapsulated sirolimus (NAS) which mitigates the formation of anti-drug antibodies (ADAs) and a uricase, pegadricase (P), which reduces serum uric acid. ADAs develop due to unwanted immune responses to biologic medicines, reducing their efficacy and tolerability, which remains an issue across multiple therapeutic modalities and disease states including uncontrolled gout.
About VONJO® (pacritinib)
VONJO is a kinase inhibitor that is indicated in the US for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L. This indication is approved under accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
About VEXAS
VEXAS syndrome is a disease that causes inflammatory and hematologic (blood) manifestations. The syndrome is caused by mutations in the UBA1 gene of blood cells and acquired later in life. The condition is not genetically inherited.
About Sobi
Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO: SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.
Contacts For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-to-share-new-clinical-data-and-research-at-eular-2025,c4156162
The following files are available for download:
https://mb.cision.com/Main/14266/4156162/3474231.pdf
Sobi share New clinical Data and Research at EULAR 2025
View original content:https://www.prnewswire.co.uk/news-releases/sobi-to-share-new-clinical-data-and-research-at-eular-2025-302466843.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
New steel, aluminum tariffs will push construction costs higher
This story was originally published on Construction Dive. To receive daily news and insights, subscribe to our free daily Construction Dive newsletter. New tariffs on foreign steel and aluminum will raise construction costs further, adding to price spikes triggered by an initial 25% tariff on the materials earlier this year, according to a June 3 industry webinar hosted by Skanska USA. President Donald Trump increased steel and aluminum tariffs from 25% to 50% on Wednesday, doubling down on a strategy that has reshaped construction supply chains since his administration took over. Only the United Kingdom is exempt from the hike until July 9, per the U.S.-U.K. Economic Prosperity Deal. The move will inflate material costs across a range of commercial building materials, at a time when many projects stand on shaky financial ground, according to panelists. 'We're still digesting the most recent announcement of the steel and aluminum tariffs doubling,' said Rob Cantando, national director of strategic supply chain at Sweden-based developer and builder Skanska. 'We're going to be working with our supply chain partners to assess that impact over the coming weeks.' In one case study shared by Skanska, the new tariffs could add around $22 million to a $375 million healthcare development. Nearly half of that jump is tied to derivative components that embed steel or aluminum in their assemblies, according to Skanska. Panelists added these cost increases could even jump as high as 8%. But other categories are showing resistance to price swings, said Cantando. Several manufacturers that announced price hikes earlier in the year, particularly of drywall, lumber and steel studs, have since scaled back further increases. 'Many of those markets that shot up early when the first round of tariffs were announced are giving back some of those gains as these new tariff policy changes are accounted for. In addition, manufacturers and suppliers are taking action to remain competitive,' said Cantando. 'Many of them are shifting sourcing and materials to minimize the impact of tariffs. In some cases, tariffs are being partially absorbed by the supply chain.' The result is an unpredictable pricing climate. For now, structural steel escalation is hovering around 5% to 8%, but that could rise quickly, said Cantando. Coil-based steel products, including hollow structural sections and bar grating, have already surged by as much as 50% since January. Midwest aluminum premiums jumped 54% following Trump's announcement last week of the new tariffs, he added. To stay ahead of volatility, suppliers have been reworking logistics. Kawneer, a Norcross, Georgia-based manufacturer of commercial construction products, has begun rerouting cross-border contracts and adjusting production footprints across North America to avoid tariff exposure, said Sarah Andreasen, director of North American sales at Kawneer. Kawneer's architectural aluminum product range includes windows, doors, framing systems, curtain wall systems and railings. The firm's products are used on nonresidential buildings such as stadiums, offices, schools, retail and healthcare construction, according to the company. 'For us, it's been all about rediverting our supply chain,' said Andreasen. 'We have had to do a lot of work, set up production capability in different plants so that we can mitigate those types of transactions from tariffs.' On the steel side, firms such as SteelFab, a Charlotte, North Carolina-based structural steel fabricator, are working directly with owners and general contractors to create bundled purchasing agreements, said Chris Gregory, executive vice president at SteelFab. Gregory recommended locking in pricing across multiple upcoming projects by combining expected orders into a single package. 'Package projects together. Say 'It's not just 1,000 tons we're buying, we'd like 15,000 tons. What kind of deal can you structure for us to lock in price and help us with the schedule?'' said Gregory. 'That has saved a tremendous amount of money this first quarter that goes directly to the owners.' However, risks still remain, said panelists. In certain cases, tariff impacts won't appear on an invoice at all, said Cantando. For instance, if the cost of a component rises due to reshuffled sourcing or overseas market constraints, there's rarely a clean paper trail. 'A component costs $100 but because of tariffs, it now costs $150. My supply chain team quickly gets to work to try to find an alternate source. Let's say they find a source that's $125,' said Cantando. 'You can argue that the $25 increase was a result of tariffs. But you're not going to have a document that shows that because there's no tariff that's applied to it.' Tariffs' impacts are further complicated by shifting domestic capacity. While U.S. steel mills are currently running below peak capability, at around 75%, certain segments have already seen stretched lead times, said Gregory. Aluminum smelting capacity, idled in recent years, will also be harder to ramp back up, said Andreasen. 'I do think it's something that we're going to have to watch pretty carefully,' said Andreasen. 'I think that's a challenge that we'll continue to watch on the horizon.' In the meantime, executives should continue to develop contingency planning and contract strategies. Panelists during the session advised clients to revisit contracts to help mitigate risk. 'You might want to consider establishing unit pricing, or index-based pricing, for products where the supply chain is suggesting that firm fixed pricing won't reflect future tariff policies,' said Sarah Vakili, senior director of business planning and strategy at Skanska. 'Of course, stay informed and be willing to adapt.' Recommended Reading Construction costs dip, but tariffs hike some materials' prices
The Drive
2 hours ago
- The Drive
After 66 Years of the Same Old Seatbelt, Volvo Tries Something New
The latest car news, reviews, and features. The electric 2026 Volvo EX60 will be the Swedish automaker's first model to feature its new 'multi-adaptive safety belts.' This new-gen seat belt is designed to more effectively protect you in an accident with a rapid download of impending-crash data from external and internal sensors, optimizing for everything from impact speed to your posture while driving. Modern seat belts are more complicated than they might look—it's not just a ribbon of fabric stapling you into your seat. In any car, pretensioners cinch up on you in extreme deceleration, and load limiters tactically release tension to prevent the belt from hurting you. In most cars made in the last couple of decades, crash sensors communicate with the airbags and speed sensors for some range of load-limiting force adjustment. Volvo holds the honor of having introduced the now-ubiquitous three-point belt to the auto industry. Its 1959 invention is credited to Nils Bohlin. Back then, Volvo described the function of the belt: '[it] effectively, and in a physiologically favorable manner, prevents the body of the strapped person being thrown forward.' That patent was released to the public, and basically every automaker ultimately adopted it. Now, Volvo's taking that same mission, and the systemization of safety equipment, further with the multi-adaptive belt (which, surprisingly, does not have an acronym or cool-sounding proprietary brand name). Building on the idea of pretensioners and load limiters, the EX60's belts will integrate an immense amount of information—about the vehicle and passenger—to more effectively protect whoever's in the seats. An isolated view of the new belt. Volvo From the outside, vehicle direction and speed are factored in. From the inside, the EX60 will include passenger height, weight, and even posture to calculate how best to hold its passengers. 'For example, a larger occupant in a serious crash will receive a higher belt load setting to help reduce the risk of head injury. While a smaller occupant in a milder crash will receive a lower belt load setting to reduce the risk of rib fractures,' Volvo said. While Volvo's traditional seat belt has three different load-limiting profiles it can apply, this new setup has 11. That's certainly a lot more precision in the care of your body in a crash, though it's tough to extrapolate exactly how much injury reduction that will lead to. This quick teaser from Volvo's ES90 reveal video is all we've really seen of the upcoming EX60 so far. Volvo With the EX60, Volvo's promising to continuously evolve the operating scheme of the system as it gathers more real-world crash data, and apply improved logic via over-the-air updates. 'As Volvo Cars gathers more data and insights, the car can improve its understanding of the occupants, new scenarios and response strategies,' the brand stated. I haven't fallen in love with the idea of feeding my telemetry to the company that sold me my car, but this kind of safety innovation does make a case for it. Seat belts are something you never think about until you really need them. And if that ever happens, you're going to want the smartest seat belt ever engineered. Got a tip? Send us a note at tips@
Hamilton Spectator
3 hours ago
- Hamilton Spectator
Liverpool rejects Barcelona approach for Luis Diaz, AP source says
Liverpool has rejected an approach from Barcelona for forward Luis Diaz, a person with knowledge of the situation told the Associated Press on Thursday. The person spoke on the condition of anonymity because the information has not been made public. Spanish champion Barcelona is looking to strengthen, and sporting director Deco has publicly confirmed admiration for Diaz and Manchester United's Marcus Rashford. It is not known how much Barcelona was prepared to pay for Colombia international Diaz, but Liverpool informed the Catalan club he was not for sale, the person said. The 28-year-old Diaz scored 17 goals in Liverpool's Premier League title-winning campaign last season. He scored a hat trick against Bayer Leverkusen in the Champions League and was a key figure in attack for manager Arne Slot. Last month, Deco spoke to Catalan radio RAC1 and was specifically asked about Diaz and Rashford. 'We like Luis, we like Rashford, we like a series of players we have on a list that we have been working on for years,' he said. Liverpool is also looking to make additions during the offseason, with Germany midfielder Florian Wirtz a reported target. But the Merseyside club sees Diaz as an important part of its plans to retain the Premier League title next year and make a push in the Champions League. Diaz joined Liverpool from Porto in 2022 for a deal worth around 37.5 million pounds ($51 million). In that time he was won the league, FA Cup and two English League Cups, scoring 41 goals in 148 games. ___ AP sports writer Joe Wilson in Barcelona contributed. ___ James Robson is at ___ AP soccer:
